title: Glucocorticoid-remediable aldosteronism.
abstract: Glucocorticoid-remediable aldosteronism (GRA) is a monogenic form of human hypertension that predisposes to cerebral hemorrhage. As a result of a chimeric gene duplication, aldosterone is ectopically synthesized in the cortisol-secreting zona fasciculata of the adrenal gland under the control of adrenocorticotropin (ACTH). Hypertension frequently has its onset during childhood and is usually refractory to standard anti-hypertensives such as ACE inhibitors and beta-blockers. Hypokalemia can develop in those treated with a potassium-wasting diuretic, but random potassium levels are usually normal. Diagnosis has been facilitated by the availability of a genetic test. Suppression of ACTH release with exogenous dexamethasone is a useful diagnostic and therapeutic strategy. Treatment with the mineralocorticoid receptor antagonists spironolactone and epleronone is also efficacious. The diagnosis of GRA facilitates directed therapies and screening of at-risk individuals and kindreds.
authors.affiliation: Division of Endocrinology, Diabetes & Hypertension, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. gmcmahon@partners.org
authors.forename: Graham T
authors.initials: GT
authors.lastname: McMahon
authors.forename: Robert G
authors.initials: RG
authors.lastname: Dluhy
mesh_terms: D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D006929:Hyperaldosteronism / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
chemical_list: D005938:Glucocorticoids